Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TL139
- Development stage
- Phase 2
- Lead developer
- Teligene
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TL139 is an orally bioavailable, small molecule tyrosine kinase inhibitor (TKI) that dual-targets Anaplastic Lymphoma Kinase (ALK) and ROS proto-oncogene 1 (ROS1). Developed by Suzhou Taolue Biotechnology, the compound is specifically designed to address advanced solid tumors, most notably non-small cell lung cancer (NSCLC) characterized by ALK or ROS1 gene rearrangements. A key feature of TL139 is its ability to penetrate the blood-brain barrier, providing potential therapeutic benefit for patients with central nervous system (CNS) metastases, which are common in ALK/ROS1-driven cancers. It is currently being investigated in early-phase clinical trials to evaluate its safety, pharmacokinetics, and preliminary efficacy in patients with ALK- or ROS1-positive malignancies.
02
Targets
TUBB (Tubulin (alpha and beta subunits))ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on TL139.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TL139.